Search results for Narsoplimab

Narsoplimab Biosimilar – Anti-MASP2 mAb – Research Grade, ProteoGenix, PX-TA1495

Description of Narsoplimab Biosimilar - Anti-MASP2 mAb - Research Grade Narsoplimab Biosimilar – Anti-MASP2 mAb About Narsoplimab biosimilar Narsoplimab is a human monoclonal antibody. This biosimilar belong to the family of immunoglobulin G4- type. It is targeting mannan-binding lectin-associated serine protease-2 (MASP-2). This enzyme is the effector of the lectin pathway of the complement system. Narsoplimab is designed to prevent complement-mediated inflammation, but also endothelial damage, whitout interactions with other pathways of innate immunity. Indeed, Narsoplimab is developed to be a treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab’s action The lectin pathway is first activated by tissue damage and microbial infection. It is one of the principal pathways of complement system. Fortunately, inhibition of MASP-2 seems not to interfere with the classical complement pathway, which could be critical in the acquired immune response to infection. Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a complication of stem cell transplantation, which is often lethal. HSCT-TMA is a multifactorial disorder which is caused by endothelial cell damage. These could be induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and every factor associated with stem cell transplantation. A research grade biosimilar Narsoplimab biosimilar is a human antibody produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.

Narsoplimab, Abbexa, abx831454

Narsoplimab is a monoclonal antibody biosimilar expressed in Mammalian cells, targeting Mannan-Binding Lectin Serine Protease 2 (MASP2), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Narsoplimab is a Human monoclonal antibody targeting MASP2, the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity.

Research Grade Narsoplimab (HT020016), abinScience, HT020016

Narsoplimab Biosimilar - Research Grade, ichor.bio, ICH5700